We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+18.5%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$317M
AUM Growth
+$38.8M
(+14%)
Cap. Flow
-$1.56B
Cap. Flow
% of AUM
-492.71%
Top 10 Holdings %
Top 10 Hldgs %
57.22%
Holding
73
New
24
Increased
15
Reduced
14
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$15.5M |
| 2 |
Encompass Health
EHC
|
+$10.3M |
| 3 |
Cencora
COR
|
+$9.71M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$9.22M |
| 5 |
Becton Dickinson
BDX
|
+$8.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$24.4M |
| 2 |
HCA Healthcare
HCA
|
+$18M |
| 3 |
Johnson & Johnson
JNJ
|
+$13.9M |
| 4 |
Charles River Laboratories
CRL
|
+$9.93M |
| 5 |
WMGI
Wright Medical Group Inc
WMGI
|
+$7.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.13% |
| 2 | Industrials | 1.01% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dentsply Sirona
XRAY
$2.68B
| $3.21M | 1.01% |
+56,725
| New | +$3.16M |
|
|
RCM
27
DELISTED
R1 RCM Inc. Common Stock
RCM
| $3.19M | 1.01% |
246,029
-2,132,934
| -90% | -$24.4M |
|
|
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.11M | 0.98% |
29,710
+12,580
| +73% | +$1.41M |
|
29
Baxter International
BAX
$13.5B
| $2.86M | 0.9% |
+34,151
| New | +$2.83M |
|
30
Fate Therapeutics
FATE
$286M
| $2.64M | 0.83% |
135,022
-31,760
| -19% | -$504K |
|
|
ADVM
31
DELISTED
Adverum Biotechnologies
ADVM
| $2.48M | 0.78% |
+21,482
| New | +$1.89M |
|
|
SILK
32
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $2.07M | 0.65% |
+51,303
| New | +$1.8M |
|
33
CONMED
CNMD
$1.39B
| $2.01M | 0.63% |
17,940
+4,828
| +37% | +$515K |
|
34
AdaptHealth
AHCO
$1.47B
| $1.84M | 0.58% |
+167,858
| New | +$1.67M |
|
35
Prothena Corp
PRTA
$425M
| $1.74M | 0.55% |
110,135
+23,728
| +27% | +$254K |
|
36
McKesson
MCK
$100B
| $1.44M | 0.45% |
+10,396
| New | +$1.47M |
|
37
Liquidia Corp
LQDA
$7.48B
| $1.36M | 0.43% |
317,993
| – | – |
|
38
MacroGenics
MGNX
$235M
| $1.34M | 0.42% |
+122,900
| New | +$1.22M |
|
39
Tandem Diabetes Care
TNDM
$1.34B
| $1.27M | 0.4% |
+21,361
| New | +$1.32M |
|
40
Axsome Therapeutics
AXSM
$11.2B
| $1.15M | 0.36% |
+11,151
| New | +$450K |
|
41
DaVita
DVA
$15.4B
| $901K | 0.28% |
+12,002
| New | +$796K |
|
|
NCNA
42
NuCana
NCNA
$5.49M
| $666K | 0.21% |
22
-55
| -71% | -$1.86M |
|
|
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
| $593K | 0.19% |
19,362
-2,919
| -13% | -$80.8K |
|
|
SDC
44
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $517K | 0.16% |
59,178
-74,210
| -56% | -$742K |
|
|
GNCA
45
DELISTED
Genocea Biosciences, Inc.
GNCA
| $493K | 0.16% |
238,207
+50,079
| +27% | +$119K |
|
46
Sutro Biopharma
STRO
$401M
| $359K | 0.11% |
+3,267
| New | +$337K |
|
|
WMGI
47
DELISTED
Wright Medical Group Inc
WMGI
| $356K | 0.11% |
11,669
-289,722
| -96% | -$7.59M |
|
|
DRNA
48
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $303K | 0.1% |
+13,768
| New | +$277K |
|
49
Actinium Pharmaceuticals
ATNM
$26.3M
| $147K | 0.05% |
22,570
-22,569
| -50% | -$156K |
|
|
KA
50
CALL
DELISTED
Kineta, Inc. Common Stock
KA
| $108K | 0.03% |
+339
| New | +$76.2K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Endurant Capital Management held 73 positions worth $317M, up 14% from $279M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Endurant Capital Management withdrew a net $1.56B in Q4 2019, closing 19 positions and reducing 14 holdings. Its most notable exit was HCA Healthcare, an estimated $18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 77% a quarter earlier, followed by Industrials and Technology.
Against the trend, Endurant Capital Management opened a new position in Regeneron Pharmaceuticals worth $10.3M.
- Endurant Capital Management's largest Q4 2019 buy was Regeneron Pharmaceuticals: 27,390 shares worth $10.3M.
- Endurant Capital Management added most to Elevance Health in Q4 2019, an estimated $15.5M increase.
- Endurant Capital Management's biggest Q4 2019 reduction was R1 RCM Inc. Common Stock, cutting an estimated $24.4M.
- Endurant Capital Management fully exited HCA Healthcare in Q4 2019, selling an estimated $18M.
- Endurant Capital Management's ten largest holdings make up 57% of its $317M portfolio in Q4 2019.
- Endurant Capital Management opened 24 new positions and closed 19 in Q4 2019.
- Endurant Capital Management's portfolio value rose 14% quarter-over-quarter to $317M.
Based on Endurant Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.